Publications

BibTex format

@article{Capper:2020:10.1002/cbic.202000117,
author = {Capper, MS and Rehkämper, M and Packman, H},
doi = {10.1002/cbic.202000117},
journal = {ChemBioChem},
pages = {2111--2115},
title = {Rhenium-based complexes and in vivo testing: A brief history},
url = {http://dx.doi.org/10.1002/cbic.202000117},
volume = {21},
year = {2020}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The success of metalbased anticancer therapeutics in the treatment of cancer is best exemplified by cisplatin. Currently used in 32 / 78 cancer regimens, the use for metalbased therapeutics has a clear role in cancer therapy. Despite this, metalbased therapeutics are not without drawbacks, with issues such as toxic side effects and the development of resistance mechanisms. This has led to investigations of other metalbased therapeutics such as auranofin, a goldbased drug candidate as well as rutheniumbased candidates, NAMIA, NKP1339 and TLD1433. All are undergoing current clinical trials. Another class of complexes under study are rheniumbased; such complexes have undergone extensive in vitro testing but only seven have displayed antitumor in vivo activity which is a necessary step before entering clinical trials. This present review will document, chronologically, the rheniumbased drug candidates that have undergone in vivo testing and the outlook for such complexes.
AU  - Capper,MS
AU  - Rehkämper,M
AU  - Packman,H
DO  - 10.1002/cbic.202000117
EP  - 2115
PY  - 2020///
SN  - 1439-4227
SP  - 2111
TI  - Rhenium-based complexes and in vivo testing: A brief history
T2  - ChemBioChem
UR  - http://dx.doi.org/10.1002/cbic.202000117
UR  - https://onlinelibrary.wiley.com/doi/abs/10.1002/cbic.202000117
UR  - http://hdl.handle.net/10044/1/77610
VL  - 21
ER  -

Download

Professor Mark Rehkämper

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)